Success Metrics

Clinical Success Rate
95.8%

Based on 23 completed trials

Completion Rate
96%(23/24)
Active Trials
0(0%)
Results Posted
83%(19 trials)
Terminated
1(4%)

Phase Distribution

Ph phase_3
14
54%
Ph phase_4
2
8%
Ph early_phase_1
1
4%
Ph phase_2
1
4%
Ph not_applicable
1
4%
Ph phase_1
7
27%

Phase Distribution

8

Early Stage

1

Mid Stage

16

Late Stage

Phase Distribution26 total trials
Early Phase 1First-in-human
1(3.8%)
Phase 1Safety & dosage
7(26.9%)
Phase 2Efficacy & side effects
1(3.8%)
Phase 3Large-scale testing
14(53.8%)
Phase 4Post-market surveillance
2(7.7%)
N/ANon-phased studies
1(3.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

92.0%

23 of 25 finished

Non-Completion Rate

8.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

26

all time

Status Distribution
Completed(23)
Terminated(2)
Other(1)

Detailed Status

Completed23
unknown1
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
26
Active
0
Success Rate
95.8%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (3.8%)
Phase 17 (26.9%)
Phase 21 (3.8%)
Phase 314 (53.8%)
Phase 42 (7.7%)
N/A1 (3.8%)

Trials by Status

completed2388%
unknown14%
terminated14%
withdrawn14%

Recent Activity

0 active trials
Showing 5 of 26
completedphase_3

Gan & Lee Insulin Glargine Target Type (1) Evaluating Research

NCT03371082
completedphase_3

Gan & Lee Insulin Glargine Target Type (2) Evaluating Research

NCT03371108
completedphase_3

Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus® in Type 1 Diabetes Mellitus (T1DM) Patients

NCT02666430
completedphase_3

Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2)

NCT02227875
completedphase_3

Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1)

NCT02227862
View all 26 trials

Clinical Trials (26)

Showing 20 of 26 trialsScroll for more
NCT03371082Phase 3

Gan & Lee Insulin Glargine Target Type (1) Evaluating Research

Completed
NCT03371108Phase 3

Gan & Lee Insulin Glargine Target Type (2) Evaluating Research

Completed
NCT02666430Phase 3

Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus® in Type 1 Diabetes Mellitus (T1DM) Patients

Completed
NCT02227875Phase 3

Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2)

Completed
NCT02227862Phase 3

Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1)

Completed
NCT03338010Phase 3

A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus

Completed
NCT03338023Phase 3

A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus

Completed
NCT03555305Phase 1

A Study of Insulin Glargine (LY2963016) in Healthy Chinese Participants

Completed
NCT01352663Phase 3

Immunogenicity Safety Study of Wockhardt's Recombinant Insulin Analogue in Type 1 Diabetic Patients

Withdrawn
NCT04101383Not Applicable

A Study to Compare Pharmacokinetics and Pharmacodynamics of RinGlar® to Lantus® in Type 1 Diabetes Mellitus Patients

Completed
NCT02059187Phase 3

The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)

Completed
NCT02059161Phase 3

A Study of the Safety and Efficacy of MK-1293 Compared to Lantus™ in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003)

Completed
NCT02302716Phase 3

A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus

Completed
NCT02915250Phase 1

A Trial to Compare Post Prandial Blood Glucose Control of BioChaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes

Completed
NCT02514850Phase 1

A Trial to Compare the Pharmacodynamic and Pharmacokinetic Properties of Biochaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes

Completed
NCT02587741Early Phase 1

Comparison of Diabetes Retinopathy Among Type 2 Diabetic Patients Treated With Different Regimens

Unknown
NCT00767000Phase 2

Dose Range Finding Study of MK-0941 in Patients With Type 2 Diabetes Mellitus on Insulin (MK-0941-007 AM3 EXT1 AM1)(TERMINATED)

Terminated
NCT01421459Phase 3

A Study in Adults With Type 2 Diabetes

Completed
NCT01421147Phase 3

A Study in Adults With Type 1 Diabetes

Completed
NCT01476345Phase 1

A Study to Compare the Pharmacokinetics and Pharmacodynamics of LY2963016 to Lantus in Healthy Participants

Completed

Drug Details

Intervention Type
DRUG
Total Trials
26